Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;15(2):190-200.
doi: 10.1007/s11764-020-00923-6. Epub 2020 Nov 13.

The course of peripheral neuropathy and its association with health-related quality of life among colorectal cancer patients

Cynthia S Bonhof  1   2 , Lonneke V van de Poll-Franse  3   4   5 , Dareczka K Wasowicz  6 , Laurens V Beerepoot  7 , Gerard Vreugdenhil  8 , Floortje Mols  3   4
Affiliations

The course of peripheral neuropathy and its association with health-related quality of life among colorectal cancer patients

Cynthia S Bonhof et al. J Cancer Surviv. 2021 Apr.

Abstract

Purpose: To gain more insight into the course of chemotherapy-induced peripheral neuropathy (CIPN) and its impact on health-related quality of life (HRQoL) in a population-based sample of colorectal cancer (CRC) patients up to 2 years after diagnosis.

Methods: All newly diagnosed CRC patients from four hospitals in the Netherlands were eligible for participation in an ongoing prospective cohort study. Patients (n = 340) completed questions on CIPN (EORTC QLQ-CIPN20) and HRQoL (EORTC QLQ-C30) before initial treatment (baseline) and 1 and 2 years after diagnosis.

Results: Among chemotherapy-treated patients (n = 105), a high sensory peripheral neuropathy (SPN) level was reported by 57% of patients at 1 year, and 47% at 2-year follow-up, whereas a high motor peripheral neuropathy (MPN) level was reported by 47% and 28%, at years 1 and 2, respectively. Linear mixed model analyses showed that SPN and MPN symptoms significantly increased from baseline to 1-year follow-up and did not return to baseline level after 2 years. Patients with a high SPN or MPN level reported a worse global quality of life and a worse physical, role, emotional, cognitive, and social functioning compared with those with a low SPN or MPN level.

Conclusions: Future studies should focus on understanding the mechanisms underlying CIPN so targeted interventions can be developed to reduce the impact of CIPN on patient's lives.

Implications for cancer survivors: Patients need to be informed of both CIPN and the impact on HRQoL.

Keywords: Colorectal cancer; Health-related quality of life; PROFILES; Peripheral neuropathy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Flowchart of the study. *Characteristics of eligible CRC patients were obtained from the Netherlands Cancer Registry. †Among chemotherapy-treated CRC patients only, 76% completed 1-year follow-up and 79% completed 2-year follow-up
Fig. 2
Fig. 2
Course of sensory, motor, and autonomic peripheral neuropathy among colorectal cancer patients, stratified by chemotherapy. A higher score on the scales indicates more neuropathy symptoms. The scale in this figure ranges from 0 to 50 for clear visibility of the course of the peripheral neuropathy symptoms, while total scores of the EORTC QLQ-CIPN20 range from 0 to 100
Fig. 3
Fig. 3
Course of health-related quality of life for colorectal cancer patients according to them ever or never reporting high sensory peripheral neuropathy (a) or motor peripheral neuropathy (b). *Significant difference between patients who “ever” reported high SPN/MPN and those who “never” reported high SPN/MPN, but of no clinical relevance. ‡Significant difference, of small clinical relevance. †Significant difference, of medium clinical relevance. ¥Significant difference, of large clinical relevance. The scale in this figure ranges from 50 to 100 for clear visibility of the association between peripheral neuropathy and health-related quality of life, while total scores of the EORTC QLQ-C30 range from 0 to 100
See this image and copyright information in PMC

References

    1. Siegel RL, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–193. doi: 10.3322/caac.21395. - DOI - PubMed
    1. Nederlandse Kankerregistratie. Cijfers over Kanker. Available from: http://www.cijfersoverkanker.nl/. Accessed 12 Nov 2019.
    1. Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461–2470. doi: 10.1016/j.pain.2014.09.020. - DOI - PubMed
    1. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL, American Society of Clinical Oncology Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941–1967. doi: 10.1200/JCO.2013.54.0914. - DOI - PubMed
    1. Gutiérrez-Gutiérrez G, et al. Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. Clin Transl Oncol. 2010;12(2):81–91. doi: 10.1007/S12094-010-0474-z. - DOI - PubMed

Publication types

MeSH terms

Substances